CortesJRousselotPKimD-W. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207-3213.
2.
HaznedarogluIC. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations. Expert Opin Pharma-cother. 2013;14:2005-2010. doi:10.1517/14656566.2013.833185.
3.
SiddiquiMAScottLJ. Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs. 2007;67:805-820.
4.
KantarjianHMShahNPCortesJE. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119:1123-1129. doi:10.1182/blood-2011-08-376087.
5.
PenelNBlayJYAdenisA. Imatinib as a possible cause of severe rhabdomyolysis. N Engl J Med. 2008;358:2746-2747. doi:10.1056/NEJMc0708896.
6.
GordonJKMagidSKMakiRGFleisherMBermanE. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). Leuk Res. 2010;34:827-829. doi:10.1016/j.leukres.2009.11.002.
7.
NakashimaSFujitaYMatsuoH. Two cases of surgical resection of rectal gastrointestinal stromal tumor after neoadjuvant therapy with imatinib mesylate [in Japanese]. Gan To Kagaku Ryoho. 2012;39:1932-1934.
8.
BermanENicolaidesNMakiR. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354:2006-2013.
9.
Huerta-AlardínALVaronJMarikPE. Bench-to-bedside review: rhabdomyolysis—an overview for clinicians. Crit Care. 2005;9:158.
